Uncertainty Remains Over The Future Of Regulatory Data Protection In The EU

As talks continue on the EU pharmaceutical legislative reform proposals, drug firms may have to wait some time before they find out what the future periods of regulatory data protection and orphan market exclusivity will be.

Many flags in front of the EU Commission building in Brussels
• Source: JLBvdWOLF / Alamy Stock Photo (JLBvdWOLF / Alamy Stock Photo/Alamy Stock Photo)

The EU regulatory data protection regime is facing one of the biggest shake-ups in 20 years, with proposals by the European Commission to reduce the baseline period of RDP and introduce a system under which a set of top-up protection periods could be granted under certain conditions.

While the move to cut RDP is controversial in itself, companies that will be affected by this change – R&D-based...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Outlook

Outlook 2025: Will Geopolitics Dampen Pharma’s Comeback Party?

 
• By 

The financial macroenvironment may be looking more favorable for 2025 but will pharma growth be muted by elements beyond its control? In Vivo discusses the headwinds and drivers for pharma in the coming 12 months.

Biopharma Plumps Pipeline With Healthy Weight Loss Candidates

 
• By 

Despite the stellar success of the class so far, biotech is now looking past GLP-1s to more tolerable, sustainable approaches to obesity.

Benzos to Breakthroughs: Bill Burns on Roche's Transformation

 
• By 

Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.

Medtech Industry Reaches New Chapter In Its Structural Evolution

 
• By 

The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.

More from Market Access

US Health System Redesign Critical, NAM’s Medical Experts Warn Trump Government

 
• By 

The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.

Future Of 340B Rebate Models Hinges On Regulatory Decision Point

 
• By 

As pharmaceutical companies seek to transform how drug discounts are delivered under the 340B program, a federal ruling reinforces HRSA's authority. The industry must now wait for critical guidance from the Trump administration that could reshape compliance strategies and financial outcomes.

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By 

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.